GFT505: Phase IIb started

Genfit began the double-blind, placebo-controlled, international, pivotal Phase IIb GFT505-212-7 trial to evaluate once-daily oral GFT505 for 52 weeks in about 270 diabetic and non-diabetic NASH patie...